Press Releases

  • Cyxone's CEO Kjell G. Stenberg increases holding in the company for private account

    September 13, 2019 14:05 (CEST)

    Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company's CEO Kjell G. Stenberg has for private account increased his stake in the company by acquiring an additional 9,154 shares at a share price of 5.89 SEK.

  • Cyxone’s chairman of the board Bert Junno expands his holding in the company and exercises warrants

    September 11, 2019 11:53 (CEST)

    Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company’s chairman of the board Bert Junno increases his holding in Cyxone by exercise of 100 000 warrants.

  • Cyxone’s CEO Kjell G. Stenberg expands his private holdings in the company

    September 11, 2019 08:43 (CEST)

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company's CEO Kjell G. Stenberg has increased his private holdings in the company by acquiring 9,077 shares at a share price of 5.94 SEK.

  • Mangold Insight publishes company analysis of Cyxone

    September 10, 2019 12:23 (CEST)

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that an analysis of the company has been published by Mangold Insight.

  • First Berlin Equity Research publishes independent analysis of Cyxone

    September 6, 2019 13:13 (CEST)

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.

  • Cyxone explores orphan drug designation for Rabeximod

    September 4, 2019 14:45 (CEST)
    Regulatory

    Cyxone (publ), a Swedish biotechnology company in autoimmune diseases, today announced that the company's board of directors has decided to explore the possibilities of an orphan drug designation (ODD) of the drug candidate Rabeximod. An orphan drug status would mean that the drug candidate obtains a strengthened position under the Orphan Drug Act, as well as prevails under special regulatory frameworks designed to endorse development and shorten time to market. This is part of the continuous work to strengthen the control position of the company's own assets.

  • Cyxone’s CEO Kjell G. Stenberg acquires additional shares in the company

    August 29, 2019 12:05 (CEST)
    Regulatory

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company’s CEO Kjell G. Stenberg has for private account increased his ownership in the company through the acquisition of additional share.

  • Interim Report January 1st to June 30th, 2019

    August 28, 2019 08:30 (CEST)
    Regulatory

    Summary of the interim report

  • Cyxone strengthens team ahead of continued development of T20K and Rabeximod

    August 23, 2019 12:23 (CEST)
    Regulatory

    Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company is expanding its team with Malin Berthold as project manager for the next step in the development of Cyxone's clinical drug portfolio. Malin will primarily lead and coordinate the preclinical and clinical development programs in the company. She will be the company's primary contact with external key partners such as CROs, toxicology laboratories, pharmaceutical manufacturers, formulation experts, analysis laboratories and communication experts. Further responsibility is to regularly report the development of the projects to the company's management.  

  • Cyxone’s T20K shows favorable safety and tolerability in first-in-human trial

    August 1, 2019 17:34 (CEST)
    Regulatory

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the clinical phase I trial with drug candidate T20K successfully achieved its purpose of confirming T20K’s safety and tolerability in humans. There were no reports of serious adverse events in this infusion study. T20K, which is under development for the treatment of multiple sclerosis (MS), will as a next step in the development program be prepared as an oral formulation followed by a further clinical phase I study.